Lifecare AS acquires Cantimed UG and broadens its biosensing capabilities

Lifecare AS has acquired 100% ownership of the German company Cantimed UG, following a share purchase agreement with Nanoscale Systems Nanoss GmbH.

The transaction includes a license ensuring Lifecare´s access to the patented Nano3DSense technology in the medical field. This implies a continuation of Lifecare’s license covering the field of diabetes originally established in 2018 – and in addition broadens the Lifecares license to cover the entire medical field. This is opening significant business opportunities for Lifecare to developing additional nanobiosensors.

“The patented Nano3DSense technology is a key production method to miniaturize the Sencell sensing system, which will be based on highly sensitive micro-electronic mechanical systems and nano-cantilevers”, says Lifecare CSO Prof. Andreas Pfützner.

The combination of Lifecares proprietary Sencell technology and the Cantimed- licensed Nanos3DSense technology positions Lifecare as an innovative nanobiosensor company.

Cantimed will form the new operational basis of Lifecare in Germany as the development of Sencell and other various nanobiosensors based on Lifecares proprietary technologies evolves.

The ownership of Cantimed enables Lifecare to introduce this unique sensing system for glucose and many other analytes both in combination with the Sencell technology and as stand-alone nanobiosensors to cover a wide range of medical applications.

“In combination with the previously announced intention from the European Patent Office to grant Lifecare a new patent for the improved Sencell sensing system based on two chambers, and the extended cooperation with Bath University to develop chemistry solutions for additional analytes to fully use the improved osmotic-pressure based sensors, Lifecare is strategically well positioned to exploit the potential of the Nano3DSensing technology”, says Joacim Holter, Lifecare CEO. “The implication of this transaction is important for Lifecare. Not only does it strengthen the ownership to our basic developments, but it also positions Lifecare as a leading company within the field of nanobiosensor developments”.